Marty Shtrubel

About the Author Marty Shtrubel


Covid-19: Could Bellerphon Therapeutics’ INOpulse Help Address Hospital Ventilator Shortage?

Last year, according to the World Economic Forum, 77,000 new ventilators were enough to meet the market demand worldwide. For context, this month …

From Cancer to COVID-19, Aim ImmunoTech’s Ampligen Shows Promise

Little known biotech Aim ImmunoTech (AIM) has soared by a massive 382% year-to-date. Yet, Maxim’s analyst Jason McCarthy argues the $75 million market …

Put Amazon (AMZN) Stock on Your Grocery List, Says Top Analyst

Is anything going to stop Amazon’s (AMZN) march towards world domination? It certainly won’t be COVID-19.

Oppenheimer Doesn’t Expect a Rebound for Beyond Meat Stock Anytime Soon

Beyond Meat (BYND) worn a few hats since becoming publicly traded in May last year. From May to July BYND stock wore the …

Zoom Is a Great Company, But the Stock Is Overvalued, Says 5-Star Analyst

Zoom’s (ZM) penetration of the mainstream came seemingly out of nowhere. It is hard to remember that outside of business circles, not many …

Tesla: Despite Record Q1 Numbers, Uncertainty Looms Ahead

Tesla (TSLA) and its mercurial CEO Elon Musk are never far from the headlines and not always for the right reasons, but last …

Is 14% Potential Upside Good Enough to Risk Buying Zoom Stock? This Analyst Says Yes

Until flaws regarding Zoom’s (ZM) security started botching its mercurial ascent, you could argue the videoconferencing platform was the out and out tech …

This Penny Stock Joins the Fight Against Coronavirus; Analyst Sees Triple-Digit Upside

With a market cap of a miniscule $10.16 million, you can firmly place biotech Capricor Therapeutics (CAPR) in the nano cap section.

Coronavirus Fighter Gilead Sciences Might Be Expensive, but It’s Still Worth Owning

Gilead Sciences (GILD) has positioned itself at the front line in the global war against COVID-19. The biotech’s experimental drug remdesivir is currently …

Amarin (AMRN) Will Make Excellent Takeover Target, Says Analyst

Every time a door shuts, another window of opportunity opens, the old saying sort of goes. At least that is how one analyst …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts